Scientists Discover a Molecular Switch That Drives T-Cell Exhaustion in Cancer Immunotherapy

One of the most stubborn obstacles in modern cancer immunotherapy is a phenomenon known as T-cell exhaustion. T cells are the immune system’s primary cancer-killing cells, but when they are exposed to tumor signals for long periods of time, they gradually lose their ability to recognize and destroy cancer cells. This slow loss of function is a major reason why many immunotherapies, including CAR T-cell therapies, tumor-infiltrating lymphocyte therapies and T-cell receptor-engineered treatments, produce impressive short-term responses in solid tumors but fail to maintain durable control over time. Now, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have identified a key molecular pathway that drives this exhaustion, and their findings suggest that disabling it could help engineered immune cells stay active longer and fight solid tumors more effectively.

The study, published in the journal Cancer Immunology Research, a journal of the American Association for Cancer Research, used a powerful genetic screening technique called a genome-wide CRISPR screen to systematically search for the genes involved in T-cell exhaustion. The research team, led by senior author Dr. Antoni Ribas, professor of medicine at the David Geffen School of Medicine at UCLA and director of the cancer center’s Tumor Immunology & Immunotherapy Program, focused on human CD8+ T cells engineered to recognize a melanoma antigen. By turning off thousands of genes one by one and repeatedly exposing the engineered T cells to tumor cells in a laboratory system designed to mimic the chronic tumor exposure seen in patients with solid tumors, the investigators were able to pinpoint which genetic changes helped the immune cells remain functional, active and capable of killing cancer cells during repeated encounters with their targets.

Justin Saco, a graduate student in the Ribas laboratory and first author of the study, explained that the experimental design was a critical part of the discovery. Instead of studying short-term T-cell activation, the team modeled the chronic, repeated tumor exposure that T cells experience in solid tumors. This repeated tumor rechallenge system allowed the researchers to identify regulators of long-term persistence and exhaustion more effectively than conventional approaches. Saco noted that immunotherapy depends on T cells staying active long enough to continuously recognize and kill cancer cells, and that if they lose function too early, tumors can grow back or escape immune control. The longer T cells remain functional, the better the chance of durable cancer control.

The screening process revealed a strong and consistent signal pointing to a protein-regulating pathway known as the Cullin-5 RING E3 ligase complex, or CRL5. This molecular machinery helps control how cells break down and recycle proteins, a fundamental process that influences many aspects of cellular behavior. Importantly, the signal was not limited to a single gene. Several different components of the CRL5 machinery were independently enriched across experiments and time points, a pattern that often suggests a biologically important pathway rather than a statistical fluke. This convergence of evidence from multiple independent components of the same complex gave the researchers confidence that CRL5 plays a central role in driving T-cell exhaustion.

When the researchers disrupted CRL5-related genes, the modified T cells maintained stronger tumor-killing ability, produced higher levels of immune signaling molecules, showed fewer molecular signs of exhaustion and preserved gene programs linked to survival and long-term immune function. In other words, silencing this pathway helped the engineered immune cells resist the gradual loss of function that normally occurs during chronic tumor exposure. The modified T cells stayed active longer, produced stronger anti-tumor responses and retained the molecular characteristics of functional, persistent killer cells rather than exhausted ones.

The team also tested a drug called MLN4924, which blocks the activation of Cullin-RING ligases, including CRL5. The drug partially reproduced the effects seen with genetic deletion, helping T cells maintain stronger long-term function in laboratory experiments. This pharmacological validation is significant because it suggests that the pathway could potentially be targeted with drugs rather than requiring genetic modification of the immune cells. In mouse models of human melanoma, animals treated with CRL5-deficient T cells showed improved tumor control compared with those receiving standard engineered immune cells, providing preclinical evidence that targeting this pathway could translate into better anti-tumor responses in living organisms.

The findings suggest that targeting the CRL5 pathway could potentially help improve the durability and effectiveness of T-cell-based immunotherapies for patients with solid tumors. By reducing a key biological mechanism that drives T-cell exhaustion, it may be possible to help immune cells stay active longer and maintain their cancer-fighting ability, potentially leading to stronger and more sustained treatment responses. This could be especially valuable for CAR T-cell therapies and other forms of adoptive cell therapy, which often struggle to remain effective over time in solid tumors where the immune cells are exposed to persistent tumor signals.

A companion research article by the research group of Dr. Julia Carnevale of the University of California, San Francisco provides additional support for the findings and for the broader potential of targeting molecular mechanisms of T-cell exhaustion to improve cancer immunotherapy. The convergence of evidence from two independent research groups strengthens the case that the CRL5 pathway is a biologically important regulator of T-cell persistence and that interfering with it could open new avenues for therapeutic development.

The study’s senior author, Dr. Antoni Ribas, is also the director of the Parker Institute for Cancer Immunotherapy Center at UCLA and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. Other UCLA authors include Daniel Karin, J.J. Patten, Yichen Fan, Egmidio Medina, Nataly Naser Al Deen, Ameya Champhekar, Katie Campbell and Cristina Puig-Saus. The research was funded in part by the Parker Institute for Cancer Immunotherapy, the National Institutes of Health and philanthropic support. As the field of cancer immunotherapy continues to evolve, discoveries like this one highlight the importance of understanding the fundamental molecular mechanisms that govern immune cell function, and they point toward new strategies for engineering longer-lasting, more effective treatments for patients with solid tumors.

Subject of Research: A UCLA study identifies the Cullin-5 RING E3 ligase complex as a driver of T-cell exhaustion and shows that blocking it improves the persistence and anti-tumor function of engineered immune cells in preclinical models.

Article Title: UCLA researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy

Article References: UCLA researchers identify key pathway that drives T-cell exhaustion in cancer immunotherapy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: T-cell exhaustion, Cancer immunotherapy, CAR T-cell therapy, CRISPR screen, CRL5, Cullin-RING ligase, Solid tumors, Melanoma, Adoptive cell therapy, Cancer Immunology Research, UCLA, MLN4924